Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 5 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

40%

2 trials in Phase 3/4

Results Transparency

0 of 3 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 2

3(60.0%)

Phase 3

1(20.0%)

Phase 4

1(20.0%)

5Total

Phase 2(3)

Phase 3(1)

Phase 4(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials

NCT00239915Phase 2Completed

Safety and Efficacy Study of the Investigational Drug Pagoclone, in the Treatment of Persistent Developmental Stuttering (PDS)

Role: lead

NCT00174525Phase 2Unknown

Safety Study of Passive Immunization for Patients With Mild to Moderate Alzheimer's Disease

Role: lead

NCT00239954Phase 3Unknown

Escitalopram Combination Comparison Study for Adult Patients With Major Depressive Disorder

Role: lead

NCT00290914Phase 2Completed

Safety and Efficacy Study of Vilazodone and Discovering Genetic Markers Associated With Response in Patients With Major Depressive Disorder

Role: lead

NCT00935298Phase 4Completed

Initial Dosage Range of Tacrolimus by Genotyping in Chinese Renal Transplantation

Role: collaborator

All 5 trials loaded